BINDING OF ALUMINUM TO PLASMA-PROTEINS - COMPARATIVE EFFECT OF DESFERRIOXAMINE AND DEFERIPRONE (L1)

被引:24
作者
FERNANDEZMARTIN, JL [1 ]
MENENDEZFRAGA, P [1 ]
CANTEROS, MA [1 ]
DIAZLOPEZ, JB [1 ]
CANNATAANDIA, JB [1 ]
机构
[1] HOSP GEN ASTURIAS,UNIDAD INVEST METAB OSEO & MINERAL,E-33080 OVIEDO,SPAIN
关键词
ALUMINUM; CHELATING AGENTS; DEFERIPRONE; DESFERRIOXAMINE; PROTEIN BINDING;
D O I
10.1016/0009-8981(94)90266-6
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 [基础医学];
摘要
Ultramicrofiltration techniques were used to study both the binding of aluminium to high molecular weight proteins in the presence of different concentrations of desferrioxamine and deferiprone (LI) and the kinetics of aluminium release from human serum proteins, Human serum from healthy volunteers was used in all studies, The serum was spiked with aluminium (100 mu g/l) and different concentrations of chelators. Ultramicrofiltration was performed with Amicon YMT membranes which had a nominal cut-off of 30 000 Da. Aluminium was measured by graphite furnace atomic absorption spectrometry in total serum and ultrafiltered fluid, Deferiprone shows a higher capability to displace aluminium from serum proteins (80%) than desferrioxamine (60%) at equivalent concentrations of the chelators. The kinetics of the release were also faster for deferiprone, taking 20 min to achieve its maximum effect, whereas, desferrioxamine achieved only 80% of its maximum effect after 2 h. Thus, deferiprone could be an attractive alternative to desferrioxamine, as an aluminium chelator agent.
引用
收藏
页码:137 / 145
页数:9
相关论文
共 37 条
[1]
ACKRILL P, 1980, LANCET, V2, P692
[2]
Ackrill P, 1993, Contrib Nephrol, V102, P125
[3]
HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY METHODS FOR STUDYING PROTEIN-BINDING OF ALUMINUM IN HUMAN SERUM IN THE ABSENCE AND IN THE PRESENCE OF DESFERRIOXAMINE [J].
ALONSO, JIG ;
GARCIA, AL ;
PARAJON, JP ;
GONZALEZ, EB ;
MEDEL, AS ;
CANNATA, JB .
CLINICA CHIMICA ACTA, 1990, 189 (01) :69-80
[4]
BERCOVITCH M, 1994, LANCET, V343, P1471
[5]
BERTHOLF RL, 1986, TRACE ELEM MED, V3, P157
[6]
BERTHOLF RL, 1984, BIOCHEM BIOPH RES CO, V125, P1020, DOI 10.1016/0006-291X(84)91385-8
[7]
DEFEROXAMINE THERAPY AND MUCORMYCOSIS IN DIALYSIS PATIENTS - REPORT OF AN INTERNATIONAL REGISTRY [J].
BOELAERT, JR ;
FENVES, AZ ;
COBURN, JW .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1991, 18 (06) :660-667
[8]
KINETICS OF ALUMINOXAMINE AND FEROXAMINE CHELATES IN DIALYSIS PATIENTS [J].
CANAVESE, C ;
GURIOLI, L ;
DAMICONE, M ;
CARDELLI, R ;
CALIGARIS, F ;
BONGIORNO, P ;
ARNAUD, A ;
MATTIELLO, G ;
MARCHIORI, M .
NEPHRON, 1992, 60 (04) :411-417
[9]
ROLE OF IRON-METABOLISM IN ABSORPTION AND CELLULAR UPTAKE OF ALUMINUM [J].
CANNATA, JB ;
FERNANDEZSOTO, I ;
FERNANDEZMENENDEZ, MJ ;
FERNANDEZMARTIN, JL ;
MCGREGOR, SJ ;
BROCK, JH ;
HALLS, D .
KIDNEY INTERNATIONAL, 1991, 39 (04) :799-803
[10]
IRON-DEFICIENCY AND INTESTINAL ALUMINUM ABSORPTION - IMPLICATIONS FOR ERYTHROPOIETIN AND DEFEROXAMINE THERAPY [J].
CANNATA, JB ;
ALONSOSUAREZ, M ;
FERNANDEZMARTIN, JL ;
DIAZLOPEZ, B .
SEMINARS IN DIALYSIS, 1991, 4 (04) :224-226